WFIKKN2

Chr 17

WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2

Also known as: GASP-1, WFDC20B, WFIKKNRP, hGASP-1

The WFIKKN2 protein functions as a protease inhibitor containing multiple inhibitory domains that target serine proteases and metalloproteases, and specifically inhibits myostatin activity. Mutations cause disease through a gain-of-function mechanism, though specific clinical phenotypes and inheritance patterns are not established in the provided data. The gene shows tolerance to loss-of-function variants (pLI = 0.004, LOEUF = 0.755), consistent with the gain-of-function pathogenic mechanism.

Summary from RefSeq, UniProt, Mechanism
Research Assistant →
0
Active trials
7
Pubs (1 yr)
10
P/LP submissions
0%
P/LP missense
0.76
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryWFIKKN2
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
10 unique Pathogenic / Likely Pathogenic· 111 VUS of 126 total submissions
Some data sources returned errors (1)

pubtator: TimeoutError: The operation was aborted due to timeout

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.76LOEUF
pLI 0.004
Z-score 2.31
OE 0.40 (0.230.76)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.21Z-score
OE missense 0.97 (0.891.06)
378 obs / 389.8 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.40 (0.230.76)
00.351.4
Missense OE0.97 (0.891.06)
00.61.4
Synonymous OE1.13
01.21.6
LoF obs/exp: 7 / 17.4Missense obs/exp: 378 / 389.8Syn Z: -1.31
DN
0.6550th %ile
GOF
0.7126th %ile
LOF
0.2777th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

126 submitted variants in ClinVar

Classification Summary

Pathogenic9
Likely Pathogenic1
VUS111
Likely Benign2
Benign1
9
Pathogenic
1
Likely Pathogenic
111
VUS
2
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
9
0
9
Likely Pathogenic
0
0
1
0
1
VUS
0
111
0
0
111
Likely Benign
0
2
0
0
2
Benign
0
1
0
0
1
Total0114100124

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

WFIKKN2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Top 1 results · since 2015Search PubMed ↗